Target Validation INOVOTION offers in vivo efficacy and early toxicity assays using a chick embryo model, enabling rapid Go/No Go decisions. This creates a sales opportunity to position their platform as a cost-efficient screening step to de-risk early-stage oncology programs for biotech startups and academic labs.

Multi Cancer Screening The capability for multi-cancer screening supports diversification of client pipelines and can be marketed to pharmaceutical partners exploring multiple oncology indications, enabling broader revenue with existing tools.

Budget-Friendly Acceleration Emphasize time and cost savings to prospective clients who need faster R&D throughput without excessive preclinical spend. Target companies with limited budgets that can benefit from early-stage viability assessments.

Strategic Partnerships Ongoing hiring and recent engagement at industry events suggest a proactive business development posture. Leverage conferences and new personnel additions to form collaborations with universities, CROs, and biotech startups seeking scalable in vivo testing.

Growth Readiness Revenue is currently modest with external funding and a lean team. Focus sales efforts on value storytelling around risk reduction, faster decision cycles, and potential for future scale as the company expands its service capacity and client base.